Roivant Sciences Ltd.

$4.79 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical company. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploy technology to drive research and development and commercialization. Its drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Its development-stage product candidate includes Tapinarof, Cerdulatinib, IMVT-1401, ARU-1801, Namilumab, LSVT-1701, Cerdulatinib, DMVT-504, DMVT-503, ARU-2801, AFM32 and CVT-TCR-01. Its Vant family include Dermavant, Immunovant, Aruvant, Proteovant, Lysovant, Kinevant, Affivant, Cytovant, Arbutus, Sio Gene Therapies, Genevant, Silicon Therapeutics, VantAI, Lokavant, Datavant and Alyvant.

Stock Analysis

last close $4.66
1-mo return 27.7%
3-mo return -9.3%
avg daily vol. 1.42M
52-week high 16.76
52-week low 2.52
market cap. $3.0B
forward pe -
annual div. -
roe -41.2%
ltg forecast -
dividend yield -
annual rev. $61M
inst own. 50.5%

Subscribe now for daily local and international financial news